To investigate the effect of increasing oxytocin dose on likelihood of vaginal delivery following induction or augmentation of labor among gravida with BMI ! 30 and advanced maternal age (AMA). STUDY DESIGN: In this sub-analysis of a retrospective cohort study, electronic medical records of 619 obese gravida were reviewed for data on maternal characteristics and labor progression, including methods of induction, dosing of induction agents, duration of labor, mode of delivery, and peripartum complications. Obese gravida aged 14-50 years old with term, vertex, singleton deliveries from 1/2012 to 6/2017 were included. Those with multiple gestations, known aneuploidy or fetal demise, no documented maternal weight or BMI, prior cesarean delivery, and prisoners were excluded. The primary outcome was successful induction and/or augmentation of labor, which was defined as a vaginal delivery. Secondary outcomes included adverse neonatal outcomes (APGAR <7 at 5 minutes) and adverse maternal outcomes (chorioamnionitis, postpartum hemorrhage). Comparisons were made between obese gravida who received > or 20 milliunits/minute of oxytocin. The interaction between AMA and maximum oxytocin dose > 20 milliunits/minute was analyzed. RESULTS: AMA gravida were more likely to be white, married, and multiparous. No statistical interaction was found between age and dose of oxytocin, including after adjusting for parity, race, marital status, diabetes, smoking status, and gestational age. In an unadjusted analysis, age ! 35 and dose of oxytocin 20 milliunits/ minute were both individually associated with increased likelihood of vaginal delivery. In an adjusted analysis, age ! 35 was no longer significantly associated with successful induction and maximum oxytocin dose 20 milliunits/minute remained associated with increased likelihood of vaginal delivery. There were no differences in chorioamnionitis, postpartum hemorrhage, or APGAR scores with increasing oxytocin dose.
OBJECTIVE:
To investigate the effect of increasing oxytocin dose on likelihood of vaginal delivery following induction or augmentation of labor among gravida with BMI ! 30 and advanced maternal age (AMA). STUDY DESIGN: In this sub-analysis of a retrospective cohort study, electronic medical records of 619 obese gravida were reviewed for data on maternal characteristics and labor progression, including methods of induction, dosing of induction agents, duration of labor, mode of delivery, and peripartum complications. Obese gravida aged 14-50 years old with term, vertex, singleton deliveries from 1/2012 to 6/2017 were included. Those with multiple gestations, known aneuploidy or fetal demise, no documented maternal weight or BMI, prior cesarean delivery, and prisoners were excluded. The primary outcome was successful induction and/or augmentation of labor, which was defined as a vaginal delivery. Secondary outcomes included adverse neonatal outcomes (APGAR <7 at 5 minutes) and adverse maternal outcomes (chorioamnionitis, postpartum hemorrhage). Comparisons were made between obese gravida who received > or 20 milliunits/minute of oxytocin. The interaction between AMA and maximum oxytocin dose > 20 milliunits/minute was analyzed. RESULTS: AMA gravida were more likely to be white, married, and multiparous. No statistical interaction was found between age and dose of oxytocin, including after adjusting for parity, race, marital status, diabetes, smoking status, and gestational age. In an unadjusted analysis, age ! 35 and dose of oxytocin 20 milliunits/ minute were both individually associated with increased likelihood of vaginal delivery. In an adjusted analysis, age ! 35 was no longer significantly associated with successful induction and maximum oxytocin dose 20 milliunits/minute remained associated with increased likelihood of vaginal delivery. There were no differences in chorioamnionitis, postpartum hemorrhage, or APGAR scores with increasing oxytocin dose.
CONCLUSION: Dose of oxytocin >20 milliunits/minute was not associated with increased likelihood of vaginal delivery in an obese, AMA population. Dose of oxytocin 20 milliunits/minute was associated with an increased likelihood of vaginal delivery, likely related to the labor progression and patient characteristics that led to the increased oxytocin dose.
775 Timing of induction of labor in women with term PROM and maternal and neonatal outcomes OBJECTIVE: BACKGROUND: Based on data from a large randomized controlled trial on the management of women with prelabor rupture of membranes (PROM) at term (the TermPROM Study), planned induction of labor (IOL) with oxytocin, when compared to planned expectant management, may decrease the rate of maternal infection but does not affect the risk of neonatal infection and cesarean delivery (CD). However, the original analysis did not assess the PROMto-induction interval in a continuous manner. Therefore, the optimal timing of IOL remains to be determined. OBJECTIVE: To investigate the association between PROM-to-induction interval and maternal and neonatal outcomes in women with term PROM. STUDY DESIGN: METHODS: A cohort study design based on data from the TermPROM trial. At each interval from onset of PROM, maternal and neonatal outcomes were compared between women who underwent IOL and those managed expectantly at this interval. Neonatal outcomes included a composite of probable or definite neonatal infection and admission to neonatal intensive care unit (NICU). Maternal outcomes included a composite of maternal infection (chorioamnionitis or postpartum fever) and CD. RESULTS: A total of 4,564 of the 5,041 women included in the original trial met study criteria. The rate of neonatal infection was low overall (3.3AE1.1%), increased with the interval from PROM but was not different between IOL vs. expectant management at any interval (Figure 1 ). The rate of NICU admission increased with the interval from PROM and was significantly lower among women undergoing IOL compared with expectant management at any given interval within the first 13 hours from PROM (Figure 1 ). Among women who underwent IOL within the first 15 hours after PROM the rate of maternal infection remained stable at approximately 6% and was significantly lower than in women managed expectantly during this time period (Figure 1 ). The rate of CD was not affected by the interval from PROM or by IOL (Figure 1 ). The proportion of women who experienced spontaneous labor increased with the interval from PROM increasing to 40% at 15 hours after PROM (Figure 2) . CONCLUSION: CONCLUSIONS: In women with term PROM, immediate IOL can minimize the risk of maternal infection and NICU admission. However, delaying induction by up to 15 hours may allow for up to 40% of women to go into spontaneous labor without increasing the risk of infection or CD, but at the price of increased risk of NICU admission. OBJECTIVE: Previous cesarean delivery (CD) is a substantial risk factor for subsequent uterine rupture. Data is inconsistent regarding grandmultiparity (GMP, !6 th delivery) and the risk for uterine rupture. Specifically, no data exists regarding the risk associated with labor induction or augmentation in GMP women post CD STUDY DESIGN: We conducted a retrospective multicenter study including all trials of labor following one previous CD (TOLAC) between the years 2003-2015 in three tertiary hospitals. We included singleton deliveries at !24 weeks with vertex presentation. The study group comprised of GMP with one previous CD who underwent labor induction or augmentation. There were two control groups: 1) Multiparous (MP) women (2-5 th delivery) post CD undergoing labor induction/augmentation, and 2) GMP post CD without labor induction/augmentation.
The primary outcome was uterine rupture. Secondary outcomes included obstetrical and perinatal complications. RESULTS: The study population included 8,227 TOLACs. In both GMP groups mean maternal age was higher as compared to the MP group (p<0.0001), and prolonged second stage of labor rates were lower (p<0.0001).
The study group included 564 TOLACs of GMP women, 435 of which underwent labor induction and 129 underwent augmentation. No cases of uterine rupture were documented in the study group. In the MP control group, which included 1,958 TOLACs with induction/augmentation, 5 cases of uterine rupture were documented (0.3%). The second control group (GMP with no intervention) included 5,755 TOLACs with 15 uterine rupture cases (0.3%). No significant difference in uterine rupture rates was noted between the three TOLAC groups (p¼0.480)
There were no cases of intrapartum death (IPD) in the study group. The incidence of IPD in either control groups was 0.1% (p¼0.799).
CD rate was higher when induction or augmentation were applied, both in the GMP group (36%) and in the MP group (39.7%), as compared to 24.2% in the GMP group with no such intervention (p<0.0001). There was no difference in the rates of other obstetrical and perinatal complications (Table) CONCLUSION: Previous CD and labor induction and augmentation are established risk factors for uterine rupture. Grandmultiparity does not increase the risk beyond that of labor induction or augmentation during TOLAC 777 Uterine rupture risk in a trial of labor after cesarean section with previous vaginal birth 
